Aristotle University Of Thessaloniki (AUTH)
Η επίδραση της ατορβαστατίνης στην αρτηριακή πίεση και στη μικρολευκωματινουρία ασθενών με ιδιοπαθή αρτηριακή υπέρταση
Abstract
dc:descriptionThe present clinical study aimed to evaluate the potential effects of low-dose atorvastatin treatment on ambulatory blood pressure, urinary albumin excretion, insulin resistance and arterial stiffness in patients with mild hypertension and hypercholesterolemia. 50 patients with mild hypertension and hypercholesterolemia were enrolled in this single-center, double-blind, randomized, placebo-controlled study. Inclusion criteria consisted of i) mild hypertension with inadequate control under treatment or stage I hypertension of recent onset; ii) recently diagnosed hypercholesterolemia (LDL>150 mg/dl for patients at low cardiovascular risk and LDL>130 mg/dl for patients with 1-2 additional risk factors); iii) absence of hypolipidemic treatment. Patients were excluded in case of: i) current pregnancy; ii) history of myocardial infraction, unstable angina, or transient ischemic attack; iii) stage III-IV congestive heart failure; iv) chronic kidney disease; v) active liver disease; vi) history of malignancy, drug and alcohol abuse or current corticosteroid treatment. Eligible patients came to our department, after a 12-hour fast, after blood sampling, ambulatory BP recordings were started, subsequently central aortic BP and parameters of arterial stiffness and wave reflections were determined by performing applanation tonometry of peripheral arteries. Subjects were randomized to receive double-blind treatment with either atorvastatin 10 mg or masked placebo for 26 weeks. Background treatment remained unchanged. At 26 weeks all baseline measurements were repeated. The main finding of this study was that treatment with 10 mg atorvastatin daily for 26 weeks produced mild but statistically significant and clinically meaningful reductions in mean 24-hour SBP and DBP, as well as in systolic and diastolic BP loads between baseline and study-end. These BP lowering effects of atorvastatin were consistent in both daytime and nighttime periods. Treatment with atorvastatin 10mg daily for 26 weeks significantly reduced aortic PWV and wave reflections from peripheral sites as compared to placebo This improvement was associated with a parallel significant reduction in central aortic SBP and PP levels compared to placebo after 26 weeks of treatment, whereas peripheral BP at the level of brachial remained unchanged during follow-up in the atorvastatin group.Additionally, low dose atorvastatin treatment was associated with significant reduction in microalbuminuria as compared to placebo, regardless of the method being used. However, no significant alterations in insulin sensitivity were noted between baseline and study-end in atorvastatin group, as well as compared to placebo. As it was anticipated low dose atorvastatin significantly improved lipid profile, whereas placebo had no effect. Moreover, homocysteine and hs-CRP levels were significantly reduced in atorvastatin treated patients, whereas renal function remained unchanged between baseline and end of the study, in both groups.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kanaki, Angeliki
- Κανάκη, Αγγελική
Subjects
dc:subject × 8Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/43275